Published in Nature Communications, a study led by James Bertlin, CRUK-funded PhD student, and Prof. James Nathan uncovered a target in a common form of kidney cancer which offers dual therapeutic benefit: selectively killing cancer cells while simultaneously activating the immune system to attack.